Dosing begins in a Phase 2 trial of BIA 28-6156, Bial’s therapy for PwPs with mutations in the glucocerebrosidase 1 (GBA1) gene.

[jeffreyn]

"The ACTIVATE (NCT05819359) study is currently screening Parkinson’s patients, ages 35 to 80 years, across multiple sites in North America. Screening is expected to start in Europe later this year."

"The ACTIVATE trial seeks to enroll about 237 patients with Parkinson’s diagnosed between one to seven years prior to genetic screening."

"Participants will be randomly assigned to a placebo or one of two daily doses of BIA 28-6156, either 10 mg or 60 mg, for up to 78 weeks (about 1.5 years)."

PNT article:

parkinsonsnewstoday.com/new...

Study record:

clinicaltrials.gov/ct2/show...